Core Viewpoint - The proposed sale of MRC Global Inc. to DNOW Inc. is under investigation to assess whether the transaction adequately values MRC Global and the process leading to this valuation is appropriate [1]. Group 1 - MRC Global shareholders will receive 0.9489 shares of DNOW for each share of MRC they own as part of the proposed transaction [1]. - Kahn Swick & Foti, LLC is investigating the adequacy of the consideration offered to MRC Global shareholders [1]. - The investigation aims to determine if the proposed sale undervalues MRC Global [1].

Core Points - The proposed sale of iTeos Therapeutics, Inc. to Concentra Biosciences, LLC involves shareholders receiving $10.047 in cash per share, along with a non-transferable contingent value right [1] - The contingent value right includes the right to receive 100% of iTeos' closing net cash exceeding $475 million and 80% of net proceeds from the sale of certain product candidates within six months post-closing [1] - Kahn Swick & Foti, LLC is investigating whether the proposed transaction adequately values iTeos and the process leading to this valuation [1] Company and Industry Summary - iTeos Therapeutics, Inc. is currently in a proposed transaction to be acquired by Concentra Biosciences, LLC [1] - The investigation by Kahn Swick & Foti, LLC is focused on the adequacy of the transaction consideration and the valuation of the company [1][2] - The transaction is structured as a tender offer, indicating that timing is critical for stakeholders [3]